8 Nov 2017: KY1044 strongly inhibits tumour growth in models

Kymab presents data at the Society for Immunotherapy of Cancer meeting on its lead immuno-oncology antibody KY1044, showing strong potent...

Read article

21 Sep 2017: KY1005 impressive in acute GVHD model

Kymab and Seattle Children’s Research Institute publish impressive results using KY1005 in a model of acute Graft-versus-Host Disease (aG...

Read article

31 Jul 2017: Kymab's KY1005 antibody in clinical trial

Kymab announces clinical update on its promising new antibody KY1005 for the treatment of autoimmune diseases, completing dosing of the 2...

Read article

29 Jul 2017: Allan Bradley at Canaccord Genuity Growth Conference

Kymab CTO Professor Allan Bradley to present at Canaccord Genuity Annual Growth Conference on August 10, 2017

Read article

16 Jun 2017: Kymab appoints Dr Martin Nicklasson as Non-Executive Chair

Kymab Group Limited appoints Dr Martin Nicklasson as Non-Executive Chair

Read article

9 May 2017: Sonia Quaratino appointed Kymab CMO

Kymab has appointed Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group...

Read article

23 Jan 2017: Arndt Schottelius appointed Executive VP R&D

Kymab has appointed Dr Arndt Schottelius as its first Executive Vice President Research & Development. Dr Schottelius will lead Kymab's R...

Read article

9 Jan 2017: Kymab expands Infectious Disease Programmes

Kymab receives $9m grant from the Bill & Melinda Gates Foundation to fund infectious disease research and development

Read article

5 Dec 2016: Antibody shows dramatic post-transplant benefit

Kymab's new therapeutic antibody for autoimmune diseases shows potential for improvement in post-transplant survival

Read article

24 Nov 2016: Kymab secures US$100 million Series C funding

New investors ORI Healthcare Fund L.P. with participation by Shenzhen Hepalink Pharmaceutical Co., Ltd., join follow-on investments from ...

Read article

11 Oct 2016: Bispecific antibody agreement with EpimAb

Partners combine complementary bisepcific antibody technologies to create novel treatments for severe human diseases

Read article

8 Sep 2016: Kymab's early steps towards HIV vaccine

Kymouse success in new approaches that could spur the human body to produce HIV-blocking antibodies

Read article

21 Apr 2016: New therapeutic heads: Cambridge TV interview

Dave Chiswell and Paul Kellam explain how Kymouse™ will help tackle disease in key areas.

Read article

18 Apr 2016: Kymab and Heptares seek cancer therapeutics

Partnership with Heptares will develop antibodies that target GPCR proteins acting as checkpoints in cancer development.

Read article

15 Apr 2016: Kymab features on BBC News

Kymab CEO, Dr Dave Chiswell, is interviewed by BBC East Business Correspondent, Richard Bond, explaining how Kymab’s success means it wil...

Read article

14 Apr 2016: Three appointments to lead key therapeutic areas

Kymab strengthens its management team with appointments in immuno-oncology, infectious disease and blood disorders

Read article

17 Mar 2016: Dave Chiswell appointed Kymab CEO

Dave Chiswell takes on and relishes the permanent CEO role after 'one of the most satisfying years of my career' as interim CEO.

Read article

9 Mar 2016: Cambridge Business interviews Dave Chiswell

Cambridge Business' Jenny Chapman returned to speak with Dave Chiswell, as he took the permanent CEO role at Kymab, about his successes a...

Read article

2 Feb 2016: Kymab Succeeds in Revoking Regeneron’s UK VelocImmune® Patents

Cambridge, UK, 2 February 2016: Kymab Limited, a leading human monoclonal antibody biopharmaceutical company announced today that the Eng...

Read article

6 Jan 2016: MD Anderson and Kymab partnership

Kymab and the University of Texas MD Anderson announce a strategic cancer drug discovery and development alliance.

Read article

7 Sep 2015: Kymab: biotech company that is ‘One to Watch’

Kymab, the Cambridge-based antibodies-to-medicines company, features in the top ten of The Sunday Times Tech Track ‘Ones to Watch’ 2015.

Read article

6 May 2015: Kymab secures US$90 million funding

US$50 million investment from Woodford Patient Capital Trust plc and Malin Corporation plc completes US$90 million Series B financing.

Read article

19 Feb 2015: Anne Hyland appointed Chief Financial Officer

Kymab announced today the appointment of Anne Hyland as Chief Financial Officer, with effect from 1 March 2015.

Read article

9 Feb 2015: David Chiswell becomes Kymab interim CEO

David Chiswell, Kymab’s Chairman, takes over as interim CEO of Kymab until a new, permanent CEO is appointed.

Read article

16 Dec 2014: Partnership to fight Ebola virus

Kymab and the Wellcome Trust have launched a partnership to produce an antibody-based medicine to fight Ebola infection.

Read article

23 Sep 2014: New appointments strengthen Board

Following new investment, Kymab strengthens and extends capabilities through Board appointments and Executive promotions.

Read article

1 Sep 2014: Kymab profiled as Biopharma Dealmaker

Kymab has been profiled in Nature Publishing Group's Biopharma Dealmakers.

Read article

3 Jun 2014: Two senior appointments strengthen team

Kymab makes senior appointments at Chief Scientific Officer and Vice President and Head of Business Development.

Read article

16 May 2014: Gates and Wellcome Trust invest in Kymab

The Bill & Melinda Gates Foundation joins existing investor, the Wellcome Trust, with each investing US$20 million in Kymab to advance cl...

Read article

23 Apr 2014: Commentary: Improving Drug Development

With its human immune system, Kymouse™ does much of the difficult work in honing the best therapeutic antibody, suggest Kymab CEO Christi...

Read article

16 Mar 2014: Kymouse™ has full human antibody system

Scientists at Kymab have engineered a mice with the full set of human antibody genes that can produce an enormous range of human antibodi...

Read article

2 Sep 2013: Kymab appoints new CEO and Chairman

Kymab appoints Dr Christian Groendahl as Chief Executive Officer and Dr David Chiswell as Chairman.

Read article

29 Apr 2013: Kymouse HL human antibody at PEGS 2013

Allan Bradley describes how Kymouse HL™ human antibody system improves discovery of highly selective, potent, human antibody drug candida...

Read article

22 Apr 2013: Antibody agreement with Novo Nordisk

Kymab announced today an agreement with Novo Nordisk to develop monoclonal antibody drugs for human diseases.

Read article

18 Mar 2013: Appointments strengthen drug development

Dr Duncan Casson joins as Chief Development Officer, Professor Ken Smith joins SAB and Dr George Vassiliou elected Senior Clinical Fellow.

Read article

4 Feb 2013: Kymab Access to support academic translation

Kymab launches Kymab Access, an academic collaboration programme for the discovery and development of human monoclonal antibodies.

Read article

5 Dec 2012: Kymouse™ data at antibody engineering conference

Kymab to report Kymouse HK™ human antibody discovery data at the IBC Antibody Engineering Conference in San Diego, CA.

Read article

30 Nov 2012: Financial Times: Of mice, men and medicine

The Financial Times’ Clive Cookson outlines the development of Kymouse™, explaining that no mice on earth have more human DNA

Read article

29 Oct 2012: Kymab strengthens Board of Directors

Christian Itin, David Chiswell and Richard Davis join the Kymab Board as Non-Executive Directors.

Read article

30 Mar 2012: Milestone in Kymouse human antibody platform

Kymab demonstrates human-like functionality and usage, providing the genetic basis for first commercial strains.

Read article

28 Feb 2012: BioCentury ‘Emerging Company’ profile

BioCentury©, the respected Bioindustry newsletter, publishes an ‘Emerging Company’ profile on Kymab.

Read article

30 Nov 2011: Allan Bradley appointed Chief Scientific Officer

Kymab announces the appointment of Professor Allan Bradley, FRS, as Chief Scientific Officer.

Read article

18 Jan 2011: Kymab opens Cambridge R&D facility

Sir Paul Nurse and Sir Mark Walport formally open Kymab’s laboratories at Babraham Research Campus.

Read article

12 Jul 2010: Wellcome Trust £20 million financing agreement

UK biopharmaceutical company will be built based on Sanger Institute human monoclonal antibody technology.

Read article

Find out which events we'll be attending this year

View events